PacBio Q4 rev. $44.6mln, FY22 rev. $160mln, up 4% YoY.

• PacBio Q4 revenue up 14% YoY to $44.6mln • FY 2025 revenue flat at $160mln • Consumable revenue up 15% YoY to $21.6mln • Instrument revenue down 13% YoY to $17.3mln • Service and other revenue up 12% YoY to $5.7mln • Revio system placements at 212 • Vega system placements at 427 • Annualized Revio pull-through per system at $242,000 • Ending cash, cash equivalents, and investments at $279.5mln • PacBio reports GAAP and non-GAAP gross margin, operating expenses, net income (loss), and net income (loss) per share.